Skip to main content
main-content
Erschienen in: Breast Cancer 2/2014

01.03.2014 | Original Article

Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS

verfasst von: Motonobu Saito, Masami Matsuzaki, Takeshi Sakuma, Naoto Katagata, Fumiaki Watanabe, Yoshiko Yamaguchi, Aaron J. Schetter, Seiichi Takenoshita, Tadashi Nomizu

Erschienen in: Breast Cancer | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent widespread use of screening mammography has led to increased detection rates of non-palpable breast cancer. This study aimed to evaluate the clinicopathological features of non-palpable ductal carcinomas in situ of the breast that were detected by screening mammography of patients with a family history of breast cancer.

Methods

We selected 6 Japanese patients diagnosed with non-palpable breast cancer with self-reported family history of breast cancer. Mutations in BRCA1 and BRCA2 were evaluated with germ line genetic testing and immunohistochemistry (IHC) using resected specimens. Pathological features, such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, were also evaluated.

Results

The patients (ages 41–67 years; mean 53.5) had 7 tumors with one patient having synchronous bilateral breast cancer. Breast cancer was suspected from the microcalcification in 5 tumors and the distortion in 2 tumors by mammography and diagnosed by biopsy. Breast-conserving surgery was performed in 2 patients and mastectomy was performed in 4 patients. Genetic testing revealed BRCA2 gene germ line mutation in three patients. IHC of BRCA was consistent with BRCA2 mutation status.

Conclusions

The family history of breast cancer patients may lead one to suspect familial breast cancer and screening mammography is useful for the early detection of these cancers. IHC of BRCA showed staining results that were consistent with BRCA genetic testing, suggesting that it has the potential to be a useful tool in clinical practice.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. PubMedCrossRef
2.
Zurück zum Zitat Nomizu T, Sakuma T, Yamada M, Matsuzaki M, Katagata N, Watanabe F, et al. Three cases of kindred with familial breast cancer in which carrier detection by BRCA gene testing was performed on family members. Breast Cancer. 2009. doi: 10.​1007/​s12282-009-0157-1. Nomizu T, Sakuma T, Yamada M, Matsuzaki M, Katagata N, Watanabe F, et al. Three cases of kindred with familial breast cancer in which carrier detection by BRCA gene testing was performed on family members. Breast Cancer. 2009. doi: 10.​1007/​s12282-009-0157-1.
3.
Zurück zum Zitat Adem C, Jenkins RB, Capron F, Stoppa-Lyonnet D. High-risk lesions in high-risk women: a high-risk formalin-based biology! J Clin Oncol 2004;22:1159–61 (author reply 1152–61). Adem C, Jenkins RB, Capron F, Stoppa-Lyonnet D. High-risk lesions in high-risk women: a high-risk formalin-based biology! J Clin Oncol 2004;22:1159–61 (author reply 1152–61).
4.
Zurück zum Zitat Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007;25:642–7. PubMedCrossRef Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007;25:642–7. PubMedCrossRef
5.
Zurück zum Zitat Smith KL, Adank M, Kauff N, Lafaro K, Boyd J, Lee JB, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res. 2007;13:4306–10. PubMedCrossRef Smith KL, Adank M, Kauff N, Lafaro K, Boyd J, Lee JB, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res. 2007;13:4306–10. PubMedCrossRef
6.
Zurück zum Zitat Nomizu T, Tsuchiya A, Kanno M, Katagata N, Watanabe F, Yamaki Y, et al. Clinicopathological features of hereditary breast cancer. Breast Cancer. 1997;4:239–42. PubMedCrossRef Nomizu T, Tsuchiya A, Kanno M, Katagata N, Watanabe F, Yamaki Y, et al. Clinicopathological features of hereditary breast cancer. Breast Cancer. 1997;4:239–42. PubMedCrossRef
7.
Zurück zum Zitat Katagiri T, Kasumi F, Yoshimoto M, Nomizu T, Asaishi K, Abe R, et al. High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. J Hum Genet. 1998;43:42–8. PubMedCrossRef Katagiri T, Kasumi F, Yoshimoto M, Nomizu T, Asaishi K, Abe R, et al. High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. J Hum Genet. 1998;43:42–8. PubMedCrossRef
8.
Zurück zum Zitat Kim D, Jung W, Koo JS. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci. 2011;26:352–9. PubMedCentralPubMedCrossRef Kim D, Jung W, Koo JS. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci. 2011;26:352–9. PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90. PubMedCrossRef Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90. PubMedCrossRef
10.
Zurück zum Zitat Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010;28:5265–73. PubMedCrossRef Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010;28:5265–73. PubMedCrossRef
11.
Zurück zum Zitat Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 2010;7:702–7. PubMedCrossRef Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 2010;7:702–7. PubMedCrossRef
12.
Zurück zum Zitat Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc. 2010;85:1111–20. PubMedCrossRef Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc. 2010;85:1111–20. PubMedCrossRef
13.
Zurück zum Zitat Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359:1471–7. PubMedCrossRef Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359:1471–7. PubMedCrossRef
14.
Zurück zum Zitat Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437–43. PubMedCrossRef Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437–43. PubMedCrossRef
15.
Zurück zum Zitat Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer. 2005;41:2304–11. PubMedCrossRef Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer. 2005;41:2304–11. PubMedCrossRef
16.
Zurück zum Zitat Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143:362–79. PubMedCrossRef Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143:362–79. PubMedCrossRef
17.
Zurück zum Zitat Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34. PubMedCrossRef Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34. PubMedCrossRef
Metadaten
Titel
Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS
verfasst von
Motonobu Saito
Masami Matsuzaki
Takeshi Sakuma
Naoto Katagata
Fumiaki Watanabe
Yoshiko Yamaguchi
Aaron J. Schetter
Seiichi Takenoshita
Tadashi Nomizu
Publikationsdatum
01.03.2014
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 2/2014
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-012-0389-3

Weitere Artikel der Ausgabe 2/2014

Breast Cancer 2/2014 Zur Ausgabe

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.